CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus

CRISPR-based diagnostics (CRISPR-dx), including the Cas12-based DETECTR and Cas13-based SHERLOCK Class 2 CRISPRs, have been used to detect the presence of DNA or RNA from pathogens, such as the 2009 pandemic influenza virus A (IAV) and the 2019 novel coronavirus SARS-CoV-2. Here, we describe the col...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimi, Kazuto, Takeshita, Kohei, Yamayoshi, Seiya, Shibumura, Satomi, Yamauchi, Yuko, Yamamoto, Masaki, Yotsuyanagi, Hiroshi, Kawaoka, Yoshihiro, Mashimo, Tomoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801231/
https://www.ncbi.nlm.nih.gov/pubmed/35128347
http://dx.doi.org/10.1016/j.isci.2022.103830
Descripción
Sumario:CRISPR-based diagnostics (CRISPR-dx), including the Cas12-based DETECTR and Cas13-based SHERLOCK Class 2 CRISPRs, have been used to detect the presence of DNA or RNA from pathogens, such as the 2009 pandemic influenza virus A (IAV) and the 2019 novel coronavirus SARS-CoV-2. Here, we describe the collateral single-stranded DNA cleavage with Class 1 type I CRISPR-Cas3 and highlight its potential for development as a Cas3-mediated rapid (within 40 min), low-cost, instrument-free detection method for SARS-CoV-2. This assay, which we call Cas3-Operated Nucleic Acid detectioN (CONAN), not only detects SARS-CoV-2 in clinical samples, but also offers specific detection of single-base-pair mutations in IAV variants. This tool allows rapid and accurate point-of-care testing for patients with suspected SARS-CoV-2 or drug-resistant IAV infections in hospitals.

Ejemplares similares